
Fossils Reveal Final Refuge Of Ferocious Land-Living Crocs
After the demise of the dinosaurs following an asteroid strike 66 million years ago, mammals became Earth's dominant land animals. But that does not mean they went unchallenged. In South America, for instance, nightmarish land-living crocs - cousins of today's crocodiles and alligators - became apex predators.
This lineage of terrestrial crocs, called sebecids, lasted longer than previously believed, according to researchers who described fossils recently unearthed in the Dominican Republic that reveal that the islands of the Caribbean served as an unexpected last refuge for these ferocious predators.
Until now, the most recent fossils of sebecids were found in Colombia and dated to about 10.5-12.5 million years ago. The Dominican Republic fossils date to about 5-7 million years ago. The largest of the sebecids reached roughly 20 feet (6 meters) long, though the partial remains from the Dominican Republic indicate an animal up to about 7 feet (2 meters) long.
"These were the type of predators that one thinks were from the dinosaur times," said Lazaro Vinola Lopez, a graduate student in paleontology at the University of Florida and lead author of the research published this week in the journal Proceedings of the Royal Society B.
Instead, Vinola Lopez said, sebecids were at the top of the food chain in South America during the age of mammals alongside terror birds, giant flightless birds up to about 10 feet (3 meters) tall with massive hooked beaks, and saber-toothed marsupials, counterparts to the saber-toothed cats of North America and elsewhere.
Various types of crocs have inhabited Earth dating back to the Triassic Period more than 200 million years ago. Most, like the ones alive today, lived a semiaquatic lifestyle. But some conquered the marine realm and others lived exclusively on land, like the sebecids.
The sebecids were built differently than the usual semiaquatic crocs.
They had longer legs and a more upright stance, capable of running quickly to chase down prey. They had a narrow and deep skull - superficially resembling that of a meat-eating dinosaur and much different from modern crocs that have a wider and shallower skull. And the teeth of sebecids were tall and narrow with fine serrations running along the edges for cutting through meat, also similar to carnivorous dinosaurs.
Like many other crocs, they had protective armor made of bony plates called scutes embedded in their skin.
The fossils found in the Dominican Republic in 2023 were a single tooth that closely resembled those of South American sebecids and two vertebrae with characteristics that enabled the researchers to definitively conclude that these remains belonged to a sebecid.
"It is amazing to think that these fast-moving, dinosaur-like terrestrial crocs with serrated teeth specialized for cutting meat survived in the Caribbean hunting sloths, rodents and whatever else was around up until just a few million years ago," said study co-author Jonathan Bloch, curator of vertebrate paleontology at the Florida Museum of Natural History at the University of Florida.
The researchers said that fossils of two teeth apparently from a sebecid dating to about 18 million years ago that were previously discovered in Cuba and a similar one dating to around 29 million years previously found in Puerto Rico suggest that this lineage was widespread in the islands of the West Indies.
But how did land-living crocs from South America manage to get there? The researchers said their presence on the islands is another clue indicating there may have been a pathway of temporary land bridges or a chain of islands that permitted land animals to travel from South America to the Caribbean around 32-35 million years ago.
"The distance between the islands and northern South America was significantly shorter than what it is today. This likely facilitated the dispersal of sebecids from South America," Vinola Lopez said. "This shows how important islands can be as a biodiversity museum, preserving the last members of some groups that have gone extinct everywhere."
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
19-07-2025
- Economic Times
Cancer cure found? Scientists create a new mRNA vaccine that triggers strong anticancer immune response against tumours
A new approach to cancer treatment Towards a universal cancer vaccine Live Events Building on past research (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel In a major development in cancer research , scientists at the University of Florida have created an experimental mRNA vaccine that stimulates the immune system to attack tumours. According to a study published in Nature Biomedical Engineering, the vaccine, when used alongside immune checkpoint inhibitors, produced a strong antitumor effect in vaccine does not target specific cancer proteins. Instead, it activates the immune system in the same way it would respond to a virus. Researchers found that the vaccine increased the levels of a protein called PD-L1 within tumours, making them more sensitive to Elias Sayour, a paediatric oncologist at UF Health and the lead researcher, said this development could lead to a new form of cancer treatment that does not rely entirely on surgery, radiation, or chemotherapy. The research was supported by the National Institutes of Health and other leading institutions.'This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus – so long as it is an mRNA vaccine – could lead to tumor-specific effects,' said Sayour, who is also the principal investigator at the RNA Engineering Laboratory at UF's Preston A. Wells Jr. Center for Brain Tumor added, 'This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccine s to sensitise the immune system against a patient's individual tumor.'The research challenges the two current approaches in cancer-vaccine development: targeting common proteins found in cancer patients or customising a vaccine for each patient. This study suggests a third path that focuses on stimulating a broad immune response.'This study suggests a third emerging paradigm,' said Duane Mitchell, MD, PhD, a co-author of the paper. 'What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine .'Sayour has spent more than eight years developing mRNA-based cancer vaccines using lipid nanoparticles. These vaccines work by delivering messenger RNA (mRNA), a molecule that instructs cells to make specific proteins, into the body to prompt an immune year, Sayour's lab conducted a human trial using a personalised mRNA vaccine made from a patient's own tumour cells. The treatment quickly activated the immune system to fight glioblastoma, a deadly brain cancer. The new study builds on that work by testing a generalised mRNA vaccine, not specific to any virus or cancer formulation of this new vaccine is similar to the technology used in COVID-19 vaccines but is designed to prompt a general immune response rather than target a specific protein like the COVID spike the vaccine shows similar results in future human studies, it could lead to a universal tool in the fight against cancer.


Time of India
19-07-2025
- Time of India
Cancer cure found? Scientists create a new mRNA vaccine that triggers strong anticancer immune response against tumours
In a major development in cancer research , scientists at the University of Florida have created an experimental mRNA vaccine that stimulates the immune system to attack tumours. According to a study published in Nature Biomedical Engineering, the vaccine, when used alongside immune checkpoint inhibitors, produced a strong antitumor effect in mice. The vaccine does not target specific cancer proteins. Instead, it activates the immune system in the same way it would respond to a virus. Researchers found that the vaccine increased the levels of a protein called PD-L1 within tumours, making them more sensitive to immunotherapy. Explore courses from Top Institutes in Select a Course Category Public Policy CXO PGDM Others Leadership MCA Data Science Management Product Management Degree Design Thinking Data Science Cybersecurity others Finance Digital Marketing Technology Artificial Intelligence Healthcare MBA Data Analytics Project Management Operations Management healthcare Skills you'll gain: Duration: 12 Months IIM Calcutta Executive Programme in Public Policy and Management Starts on undefined Get Details Skills you'll gain: Economics for Public Policy Making Quantitative Techniques Public & Project Finance Law, Health & Urban Development Policy Duration: 12 Months IIM Kozhikode Professional Certificate Programme in Public Policy Management Starts on Mar 3, 2024 Get Details A new approach to cancer treatment Dr. Elias Sayour, a paediatric oncologist at UF Health and the lead researcher, said this development could lead to a new form of cancer treatment that does not rely entirely on surgery, radiation, or chemotherapy. The research was supported by the National Institutes of Health and other leading institutions. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo 'This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus – so long as it is an mRNA vaccine – could lead to tumor-specific effects,' said Sayour, who is also the principal investigator at the RNA Engineering Laboratory at UF's Preston A. Wells Jr. Center for Brain Tumor Therapy. Towards a universal cancer vaccine Sayour added, 'This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccine s to sensitise the immune system against a patient's individual tumor.' Live Events The research challenges the two current approaches in cancer-vaccine development: targeting common proteins found in cancer patients or customising a vaccine for each patient. This study suggests a third path that focuses on stimulating a broad immune response. 'This study suggests a third emerging paradigm,' said Duane Mitchell, MD, PhD, a co-author of the paper. 'What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine .' Building on past research Sayour has spent more than eight years developing mRNA-based cancer vaccines using lipid nanoparticles. These vaccines work by delivering messenger RNA (mRNA), a molecule that instructs cells to make specific proteins, into the body to prompt an immune reaction. Last year, Sayour's lab conducted a human trial using a personalised mRNA vaccine made from a patient's own tumour cells. The treatment quickly activated the immune system to fight glioblastoma, a deadly brain cancer. The new study builds on that work by testing a generalised mRNA vaccine, not specific to any virus or cancer mutation. The formulation of this new vaccine is similar to the technology used in COVID-19 vaccines but is designed to prompt a general immune response rather than target a specific protein like the COVID spike protein. If the vaccine shows similar results in future human studies, it could lead to a universal tool in the fight against cancer.


NDTV
18-07-2025
- NDTV
Could This Be The End Of Cancer? Scientists Develop Revolutionary mRNA Vaccine
In a significant advancement in cancer research, scientists at the University of Florida have developed an experimental mRNA vaccine that enhances the body's immune response against tumours. The study, published in Nature Biomedical Engineering, shows that this vaccine, when combined with standard immunotherapy drugs known as immune checkpoint inhibitors, produced a strong antitumor effect in mice. What makes the finding especially promising is that the vaccine doesn't target specific tumour proteins. Instead, it activates the immune system as if it were fighting a virus. This effect was achieved by boosting the expression of a protein called PD-L1 within tumours, which made them more responsive to treatment. Lead researcher Dr. Elias Sayour, a paediatric oncologist at UF Health, said in a news release this discovery could lead to a new way of treating cancer without relying solely on surgery, radiation, or chemotherapy. The study was supported by the National Institutes of Health and other major institutions. If future studies in humans show similar results, the research could pave the way for a universal cancer vaccine that helps treat many types of difficult, treatment-resistant cancers. "This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus - so long as it is an mRNA vaccine - could lead to tumor-specific effects," said Sayour, principal investigator at the RNA Engineering Laboratory within UF's Preston A. Wells Jr. Center for Brain Tumor Therapy. "This finding is a proof of concept that these vaccines potentially could be commercialized as universal cancer vaccines to sensitize the immune system against a patient's individual tumor," said Sayour, a McKnight Brain Institute investigator and co-leader of a program in immuno-oncology and microbiome research. Until now, there have been two main ideas in cancer-vaccine development: to find a specific target expressed in many people with cancer or to tailor a vaccine that is specific to targets expressed within a patient's own cancer. "This study suggests a third emerging paradigm," said Duane Mitchell, MD, PhD, a co-author of the paper. "What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine." For more than eight years, Sayour has pioneered high-tech anticancer vaccines by combining lipid nanoparticles and mRNA. Short for messenger RNA, mRNA is found inside every cell, including tumour cells, and serves as a blueprint for protein production. This new study builds upon a breakthrough last year by Sayour's lab: In a first-ever human clinical trial, an mRNA vaccine quickly reprogrammed the immune system to attack glioblastoma, an aggressive brain tumour with a dismal prognosis. Among the most impressive findings in the four-patient trial was how quickly the new method, which used a "specific" or personalised vaccine made using a patient's own tumour cells, spurred a vigorous immune system response to reject the tumour. In the latest study, Sayour's research team adapted their technology to test a "generalised" mRNA vaccine, meaning it was not aimed at a specific virus or mutated cells of cancer but engineered simply to prompt a strong immune system response. The mRNA formulation was made similarly to the COVID-19 vaccines, rooted in similar technology, but wasn't aimed directly at the well-known spike protein of COVID.